Zibb.com: Antigenics Incorporated (Web)

ANTIGENICS - Personalized cancer vaccines and other revolutionary...

The Brain Tumor Research Center at the University of California, San Francisco, has initiated a Phase 2 clinical trial evaluating the effect of Oncophage on overall survival in patients with recurrent glioma. View press release

Antigenics Incorporated

SAN DIEGO, Calif. - - ICON Group International Ltd., today released studies on labor productivity and financial benchmarks for Antigenics Incorporated (NAS: AGEN).

The Editorium

Still working the hard way? If you're editing, writing, or typesetting in Microsoft Word, our program add-ins will save you time and money and improve the editorial and typographical quality of every project.

Clinical Trial – 500,000 Words Into English in 27 Days - McElroy ...

Antigenics' project involved translation to support the clinical trial of the company’s personalized cancer vaccine. They required immediate translation of case report form (CRF) data for an upcoming interim analysis.

PRODUCT DESIGN & DEVELOPMENT CONSULTANTS | Antigenics | Community...

All logos and trademarks in this site are property of their respective owners.

Antigenics Cancer Company Profile (market briefing)

Over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

AGEN - Antigenics Inc. Stock Quotes, News, Stock Charts, Report ....

Stock quotes, news and charts for Antigenics Inc. Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,

Antigenics - Analyst News | newratings.com

Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.

EvaluatePharma - Antigenics Sample Information

EvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.

ANTIGENICS INC Share Price Stock, Quote | AGEN | | Yahoo! Finance...

Copyright 2007 (c) Yahoo! UK Ltd. All rights reserved. Questions | Disclaimer | Quotes Information Quotes delayed except where indicated otherwise. Delay time is 20 mins for London stock exchange. See also delay times for other exchanges.

Antigenics (AGEN) News - Company News and Press Releases

Track Any Stock Instantly Just enter up to ten of your stocks in the Stock Tracker box, click the ADD button beside any of Today's Hot Stocks, or click ADD beside any of the stocks you've Recently Viewed.

Pharmacy Choice - Pharmaceutical News - Antigenics reports phase ...

2006 APR 24 - (NewsRx.com) -- Antigenics, Inc., (AGEN) announced top-line results from its phase III study of Oncophage (vitespen) in kidney cancer patients who are at high risk of recurrence after surgery.

Phacilitate Advisory Boards

In October 2001, the US Food and Drug Administration (FDA) assigned Fast Track Product designation to Antigenics Oncophage® cancer vaccine for the treatment of renal cell carcinoma.

"Cancer Vaccine Test Has Promising Result"

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

IndustrialLaboratories.com | Industrial Laboratories | III Clinic...

Clinical Trial Network Provides a searchable database of clinical investigators to sponsor companies, CROs, and individuals looking to participate in clinical trials. www.clinicaltrialnetwork.com/

Antigenics slashes staff in bid to conserve cash - FierceBiotech

FierceBiotech is the biotech industry daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and fda approval news.

Antigenics CEO Receives Humanitarian Award From the Sabin Vaccine...

(CSRwire) NEW YORK--(BUSINESS WIRE)--June 29, 2006--Antigenics Inc. (NASDAQ: AGEN) today announced that the Sabin Vaccine Institute has awarded the company's chairman and CEO, Garo H. Armen, PhD, the 2006 Sabin Humanitarian Award. The Albert B.

GSK's thirst for adjuvants grows

Although alum is regarded as generally safe, cheap and has been used since the 1940s, it only prevents degradation or discharge of the antigen and does not have any immunostimulatory properties in its own right, something expected from a modern adjuvant today.

ddp direkt - Medien-Info-Service

DIE ÜBERSETZUNG INS DEUTSCHE ERFOLGT OHNE GEWÄHR. VERBINDLICH IST AUSSCHLIESSLICH DIE ORIGINALMELDUNG DES EMITTENTEN. (TRANSLATION INTO GERMAN LANGUAGE IS PROVIDED WITHOUT GUARANTEE. ONLY THE ORIGINAL MESSAGE OF THE ISSUER IS AUTHORITATIVE.

Biotechnology News and Information Portal, biotech jobs and caree...

AGEN News\r\ntoday announced that Oncophage® HSPPC96, an investigational personalized\r\ncancer vaccine, has been granted orphan drug status for the treatment of renal\r\ncell carcinoma RCC, the most common type of kidney cancer by the European\r\nMedicines Agency EMEA.

Antigenics Inc. - Securities Litigation Entwistle & Cappucci LLP ...

Antigenics Inc. Summary: According to a press release dated June 23, 2006, Antigenics Inc. announced that on June 16, 2006, a purported class action complaint was filed in the United States District Court for the District of New Mexico by Steven J.

Antigenics Cancer Company Intelligence Report

Antigenics LLC was formed as a Delaware limited liability company on 31st March 1994 and was converted to Antigenics Inc, a Delaware corporation, in February 2000.

The Scientist : Antigenics: Down, But Not Out?

Armen faced then what he estimates about 80% of all biotech companies face at some point: the potential clinical failure of its lead product. By extension, this put the survival of the company in question.

[MOL] Cancer Vaccines made to order! [01603]

Medicine On Line [Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index] [MOL] Cancer Vaccines made to order! To: "Nancy J." Subject: [MOL] Cancer Vaccines made to order! From: "Lillian" Date: Sun, 16 Apr 2000 14:54:21 -0700

DR. GARO ARMEN WINS NYC BIOTECH ENTREPRENEUR OF THE YEAR

NEW YORK - June 26, 2002 - Antigenics Inc. (Nasdaq: AGEN) today announced that Ernst & Young has awarded the company's chairman and chief executive officer, Garo H. Armen, Ph.D., New York City Biotechnology Entrepreneur of the Year. Dr.